Abstract Details

Title Edaravone (MCI-186) for the Treatment of Amyotrophic Lateral Sclerosis (ALS): A Posthoc Assessment of the 40-Item ALS Assessment Questionnaire (ALSAQ-40) by Domain

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P4 - (-)

Poster/Presentation
Number 116

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Koji Takei (Mitsubishi Tanabe Pharma Corporation) PRESENTER	No disclosure on file
Joseph M. Palumbo, MD (BioVie)	Dr. Palumbo has received personal compensation for serving as an employee of BioVie. An immediate family member of Dr. Palumbo has received personal compensation for serving as an employee of Merck Research Laboratories. Dr. Palumbo has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for BioVie. Dr. Palumbo has stock in BioVie. An immediate family member of Dr. Palumbo has stock in Merck Research Laboratories. Dr. Palumbo has received intellectual property interests from a discovery or technology relating to health care. Dr. Palumbo has received intellectual property interests from a discovery or technology relating to health care. Dr. Palumbo has received intellectual property interests from a discovery or technology relating to health care.
Kikumi Tsuda	No disclosure on file
	No disclosure on file